Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions

被引：115

作者：

Andersson, Roland ^{[1
,2
]}

Aho, Ursula ^{[1
]}

Nilsson, Bo I. ^{[3
]}

Peters, Godefridus J. ^{[4
]}

Pastor-Anglada, Marcal ^{[5
,6
]}

Rasch, Wenche ^{[3
]}

Sandvold, Marit L. ^{[3
]}

机构：

[1] Univ Lund Hosp, Dept Surg, SE-22195 Lund, Sweden

[2] Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China

[3] Clavis Pharma ASA, Oslo, Norway

[4] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Amsterdam, Netherlands

[5] Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Barcelona, Spain

[6] CIBER EHD, Barcelona, Spain

来源：

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY | 2009年 / 44卷 / 07期

关键词：

Chemoresistance; gemcitabine; pancreatic adenocarcinoma; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER-1; CELL-LINES; RESISTANCE; SURVIVAL; PHARMACOGENETICS; CHEMOTHERAPY; DETERMINANT; HMGA1;

D O I：

10.1080/00365520902745039

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Ductal pancreatic adenocarcinoma is associated with a very poor prognosis and most patients are given palliative care. Chemotherapy in the form of gemcitabine has been found to reduce disease-related pain, and the otherwise frequently occurring weight changes, to increase Karnofsky performance status and quality of life and has also resulted in a modest improvement in survival time. The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. Cellular resistance to gemcitabine can be intrinsic or acquired during gemcitabine treatment. One of the mechanisms is a decrease in hENT-1 expression. Modifications of gemcitabine not rendering it dependent on the nucleoside transporter may be a successful future mode of chemotherapy treatment, and determination of the nucleoside receptor status at the time of diagnosis could potentially also contribute to a more targeted therapy in the future.

引用

页码：782 / 786

页数：5

共 40 条

[11] In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate [J].